Enrollment in Medicare Advantage has increased dramatically over the past decade, with 51% of all Medicare beneficiaries enrolled in a Medicare Advantage plan in 2023 compared with 29% in 2013
These findings were attenuated by liraglutide therapy, demonstrating potential T-cell regulation by GLP-1 RAs in COPD [73]
Irritable Bowel Syndrome Functional gastrointestinal disorders (FGID) are multifactorial diseases with poorly characterized pathophysiology
BPC-157 has an excellent safety record with virtually no serious side effects
While the full impacts of a disrupted barrier are still being elucidated, when it is disrupted, immune response pathways are activated in intestinal tissue [9]
In a 56-day phase-2 trial, 9 participants with severe dry eye syndrome were treated with synthetic TB4 eye drops or placebo for 28 days, followed by a 28-day observational period